| Company Name: | Targacept, Incorporated | | Ticker Symbol: | TRGT | | | WWW Address: | www.targacept.com | | CEO: | Dr. J. Donald deBethizy, Ph.D. | | No. of Employees: | 112 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which is engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disorders of the central nervous system.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 22.87 |  -0.48 | 22.13 | 23.72 | 20.5119 | 23.85 | 22.59 | 122415 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 633.5 | 27.7 | 4.07 | -1.04 | 0.00 | 0.0 | 0.0 | 24.50 - 1.50 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 22.87 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 633.5 | mil |
| Latest Shares Outstanding | 27.7 | mil |
| Earnings pS (EPS) | -1.04 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 179,330 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 25.0 | mil |
| Float as % of Shares Outstanding | 99.5 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 21.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 145.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -62.8 | % |
| Pre-Tax Profit Margin | -65.7 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | -22.0 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -37.5 | % |
| Current Ratio | 5.8 | |
| Leverage Ratio (Assets/Equity) | 1.8 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.08 | |
| LT Debt/Total Capital | 5.0 | % |
| Working Capital pS | 2.35 | $ |
| Cash pS | 1.74 | $ |
| Book-Value pS | 1.69 | $ |
| Tangible Book-Value pS | 1.68 | $ |
| Cash Flow pS | -0.60 | $ |
| Free Cash Flow pS | -0.64 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 13.52 | |
| Price/Tangible Book Ratio | 13.57 | |
| Price/Cash Flow | -38.3 | |
| Price/Free Cash Flow | -35.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.6 | 101 | 2,347 | 4,104 |
| 4 Weeks | 23.89 | 18.04 | 18.75 | 22.0 | 114 | 2,569 | 43,673 |
| 13 Weeks | 24.50 | 13.98 | 14.43 | 58.5 | 147 | 2,366 | 144,297 |
| 26 Weeks | 24.50 | 2.00 | 2.84 | 705.3 | 669 | 2,849 | 356,101 |
| 52 Weeks | 24.50 | 1.50 | 2.45 | 833.5 | 756 | 1,574 | 391,844 |
| YTD | 24.50 | 2.00 | - | 542.4 | 525 | 1,684 | 382,170 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 22.37 | 21.78 | 20.58 | 11.79 | 9.28 | 4.07 | 4.07 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 36.30 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 118.99 |
| R&D | 0.00 | NA | 21.55 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 59.5 | 206.2 | 73.5 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.30 | 0.36 | 0.38 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 79.32 |
| Current Ratio | 6.7 |
| Quick Ratio (Acid Test) | 6.6 |
| Liquidity Ratio (Cash) | 6.41 |
| Receivables Turnover | 6.4 |
| Average Collection Period | 56 |
| Working Capital/Equity | 136.3 |
| Working Capital pS | 3.13 |
| Cash-Flow pS | -0.96 |
| Free Cash-Flow pS | -1.21 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 9.17 |
| Financial Leverage Ratio (Assets/Equity) | 1.7 |
| Debt Ratio | 41.8 |
| Total Debt/Equity (Gearing Ratio) | 0.08 |
| LT Debt/Equity | 0.06 |
| LT Debt/Capital Invested | 45.1 |
| LT Debt/Total Liabilities | 8.3 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.30 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 5.66 |
| Tobin's Q Ratio | 6.43 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -22.26 |
| Enterprise Value (EV)/Free Cash Flow | -18.65 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 13.57 |
| Price/Book Ratio - LTM | 13.52 |
| Price/Cash Flow Ratio | -38.3 |
| Price/Free Cash Flow Ratio - LTM | -35.9 |
| Price/Sales Ratio | 22.50 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.14 |
| Current Liabilities pS | 0.55 |
| Tangible Book Value pS - LTM | 1.68 |
| Book Value pS - LTM | 1.69 |
| Capital Invested pS | 2.19 |
| Cash pS - LTM | 1.74 |
| Cash Flow pS - LTM | -0.60 |
| Free Cash Flow pS - LTM | -0.64 |
| Earnings pS (EPS) | -1.04 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -150.93 |
| Free Cash Flow Margin 5YEAR AVG | -566.14 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.35 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.33 |
| Return on Capital Invested (ROCI) | -42.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | -26.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | -62.8 |
| EBIT Margin - LTM | -64.9 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | -4 |
| Revenue per Employee | 179,330 |
| Net Income per Employee | -229,116 |
| Average Collection Period | 37 |
| Receivables Turnover | 6.4 |
| Day's Inventory Turnover Ratio | -41 |
| Inventory Turnover | -8.7 |
| Inventory/Sales | 0.5 |
| Accounts Payble/Sales | 7.47 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | 0.26 |
| Fixed Assets Turnover | 3.05 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 0.39 |
| Revenue per $ Plant | 3.14 |
| Revenue per $ Common Equity | 0.35 |
| Revenue per $ Capital Invested | 0.33 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 32.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 204.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 204.0 |
|
|  
|
| |
 |  |